Daratumumab + VRd for transplant-eligible patients with NDMM: MRD analysis from the PERSEUS trial

MRD negativity (10⁻⁶) was higher in the D-VRd + D-R arm vs the VRd + R arm at the end of consolidation (34.4% vs 16.1%), up to 12 months (43.9% vs 20.9%), 24 months (57.7% vs 27.4%), and 36 months (63.9% vs 30.8%) and increased by ~30% during maintenance with D-R.

Among high-risk patients, D-VRd + D-R improved the MRD negativity at 10⁻⁶ (57.9% vs 30.8%) as well as sustained MRD negativity at 10⁻⁶ (30.3% vs 14.1%) vs VRd + R.

D-R maintenance was also associated with a higher proportion of MRD-positive patients converting to MRD negativity at 10⁻⁶ (56.7% vs 25.2%; p <0.0001) and sustained MRD negativity at 10⁻⁶ (31.3% vs 10.3%; p <0.0001) vs R.

Results of the MRD analysis from PERSEUS trial highlight the benefit of D-VRd followed by D-R maintenance in TE patients with NDMM, suggesting that this regimen could be the new standard of care for this patient population.